BioPharma Dive December 5, 2024
The financing is part of an upturn in investment in immunology startups this year, data from BioPharma Dive show.
Biotechnology startup Nuvig Therapeutics is the latest emerging immune drug developer to attract investors’ attention, announcing Thursday a $161 million Series B round to bring its lead candidate into mid-stage testing.
The company, which is based in Menlo Park, California, raised the funds from more than a dozen investors. It plans to use the cash to develop antibody drugs that can treat autoimmune conditions without broadly suppressing the body’s defenses, as existing immune disease therapies typically do. Nuvig’s approach could be applied to several chronic conditions, said Pamela Conley, the company’s chief scientific officer and founding CEO.
The company’s lead program...
Today's Sponsors
Today's Sponsor